David Braben

Member of the Advisory Panel

Dr David Braben OBE is the CEO of AIM quoted Frontier Developments plc, a major games developer and publisher headquartered on the Science Park in Cambridge that he founded in 1994.

David has been in the games industry for over 35 years having studied Natural Sciences at Jesus College, Cambridge, specialising in Electrical Science in his final year, before going on to study Computer Science. David is a BAFTA Fellow (one of only 96 ever awarded), is a Fellow of the Royal Academy fof Engineering, was a co-founder and still a Director/Trustee of the Raspberry Pi Foundation and a Fellow of the Institute of Engineering and Technology. David is an active investor in technology companies.

Charles Cotton

Chairman of the Advisory Panel

Charles Cotton is Founder and Chairman of Cambridge Phenomenon Ltd. He co-authored The Cambridge Phenomenon 50 Years of Innovation and Enterprise and The Cambridge Phenomenon: Global Impact. He is a Director of Frontier Developments Plc; XMOS Ltd; Cambridge Enterprise and is a member of its Investment Committees; Chairman of the Scientific Advisory Panel of Cambridge Innovation Capital; Deputy Chairman of Cambridge Ahead; a member of the Board of Trustees of the American University of Sharjah and AUS Enterprises.

Previously he was a Director of Solarflare Communications Inc. which was sold to Xilinx Inc. in August 2019; a Supervisory Board member of Euronext Amsterdam listed, Tele Atlas which was sold to TomTom for $4.3Bn in 2008; Executive Chairman of NASDAQ listed, GlobespanVirata Inc.; and CEO of Virata Corp. which he took public on NASDAQ in 1999 and achieved a market cap of more than $5Bn at its peak.

Prior to that he was President of Thermal Scientific Inc, and a Director of London Stock Exchange listed Thermal Scientific Ltd. His engagement in high technology dates back to 1983 when he was Sales and Marketing Director at Sinclair Research Ltd. After graduating, he worked in the automotive industry at British Leyland and Ford.

He holds a BA Hons in Physics from Oxford University and is a Fellow of the Institute of Physics and a Fellow of the Royal Society of Arts.

Sir Richard Friend

Member of the Advisory Panel

Professor Sir Richard Friend FRS holds the Cavendish Professorship of Physics at the University of Cambridge. His research encompasses the physics, materials science and engineering of semiconductor devices made with carbon-based semiconductors, particularly polymers. His research advances have shown that carbon-based semiconductors have significant applications in LEDs, solar cells, lasers, and electronics. These have been developed and exploited through a number of spin-off companies.  His current research interests are directed to novel schemes – including ideas inspired by recent insights into nature’s light harvesting – that seek to improve the performance and cost of solar cells.

Sir Richard is a Fellow of the Royal Society and of the Royal Academy of Engineering, and a Foreign Member of the US National Academy of Engineering.  He has received many international awards for his research, including Laureate of the Millennium Prize for Technology (2010), the Harvey Prize of the Israel Institute of Technology (2011) and the von Hippel Award of the Materials Research Society (2015). He was knighted for "Services to Physics" in the Queen's Birthday Honours List, 2003.

John Lee

Member of the Advisory Panel

John Lee is currently Chief Financial Officer of DisplayLink Corp, a market leading USB graphics software and hardware business.  He has been actively involved for many years in the Cambridge technology scene and has been Chief Financial Officer and/or an investor in a number of start-ups, many of which have resulted in successful exits or IPOs.  

Prior to his role at DisplayLink Corp, John was CEO of Velocix, a leading provider of content delivery network solutions which was sold to Alcatel-Lucent and, prior to that he was Chief Financial Officer of a number of early-stage technology based businesses.

For the past eight years John has been Chairman of the Cambridge Enterprise's Investment Committee, which currently manages assets of circa £50 million and which has had a successful track record of both investment and exit over this period.

Ruth March

Member of the Advisory Panel

Ruth March is Senior Vice President of AstraZeneca’s Precision Medicine and Genomics function. Her leadership in precision medicine led to the regulatory approval and launch of 25 new diagnostics linked to four of AstraZeneca’s precision medicines in Oncology and Inflammation.

As the member of the Innovative Medicines and Early Development leadership team responsible for patient selection, Ruth has driven the adoption of innovative precision medicine approaches by 90% of AstraZeneca’s clinical portfolio. These include the first therapeutic label based on circulating tumour DNA, the first companion diagnostic for complex laboratory testing, and the first point of care diagnostic linked to respiratory disease treatment.

Ruth leads the corporate Genomics Initiative, which aims to analyse two million genomes by 2026 to discover rare variants that underlie common disease. With 10 academic and industrial partners, the Centre for Genomics Research publishes award-winning studies at international meetings and in high impact journals.

Ruth serves as a member of Definiens’ Supervisory Board, the National Genomics Board and other advisory boards in genomics and digital health. Her academic career in the genetics of autoimmune disease was centred in London and Oxford.

Jonathan Milner

Member of the Advisory Panel

Jonathan Milner, co-founder and currently Deputy Chairman of Abcam plc, is an experienced entrepreneur and investor and is passionate about supporting UK healthcare and high-tech start-ups.  He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on AIM.

Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath University.  From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the laboratory of Professor Tony Kouzarides researching the molecular basis of breast cancer.  He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Kouzarides.

Jonathan is currently Chairman of Axol Bioscience, Camallergy Limited, Definigen Limited and PhoreMost Limited and a non-executive director of Horizon Discovery, Syndicate Room Limited, Repositive Limited, Elpis Biomedical Limited, Shift Biosciencs Limited and HealX Limited.  He also sits on the advisory board of Desktop Genetics Ltd.

Sir Keith Peters

Member of the Advisory Panel

Sir Keith Peters’ research has been on elucidation of immunological mechanisms underlying diseases of kidney and blood vessels, which has led to new treatments of these diseases.  He was Regius Professor of Physic at the University of Cambridge from 1987 to 2005, where he was also head of the School of Clinical Medicine.  Under Sir Keith’s leadership, Cambridge has become a major centre for clinical research, complementing the University’s longstanding strengths in basic biomedical science.  He is a fellow of the Royal Society, a founder Fellow of the Academy of Medical Sciences and its second President. 

From 2006-2008 Sir Keith was Interim Director of the MRC’s National Institute for Medical Research and initiated discussions which led to the establishment of the UK Centre for Medical Research and Innovation, the Francis Crick Institute.  Sir Keith is currently a consultant in Clinical Science and Translational Medicine for the Institute.  

From 2005-2016 Sir Keith was a Senior Consultant to the President of Pharmaceuticals R&D at GlaxoSmithKline and has served on the science advisory boards of various biotechnology companies including Cambridge Antibody Technology.

Andy Richards

Member of the Advisory Panel

Dr Andy Richards CBE is an entrepreneur specialising in healthcare and life sciences. He is currently Chairman of Arecor Limited, Congenica Limited, Abcodia Limited and Closed Loop Medicine Limited as well as being a Director of Ieso Digital Health Limited and Owlstone Medical Limited. He was a founder of Chiroscience Group plc and an executive director through its merger with Celltech plc in 1999.

Andy has a track record as a founder, director and active investor in more than 25 innovative healthcare and life science companies, including Vectura and Arakis. He is Chairman of Babraham Bioscience Technologies (the Babraham Campus), a director of Cancer Research Technologies and a member of CRUK. Andy is a graduate of the University of Cambridge with a PhD in Chemistry and is also a founder member of the Cambridge Angels.

John Scarisbrick

Member of the Advisory Panel

Living in Boston, MA, John Scarisbrick is a proven global technology leader with extensive board and advisory experience from high-growth start-ups to the largest enterprises.  John was Chief Executive Officer of CSR PLC between 2005 and 2007 and served on the Board of ARM Holdings plc, the world's leading microprocessor IP company, from 2001 to 2011.  Previously John worked at Texas Instruments for 25 years in variety of leadership roles in France, the UK and the USA.  He was Senior Vice President responsible for all aspects of Texas Instrument’s $5 billion+ world-wide ASP chip business.  He also served as President of TI Europe and earlier led the team that created TI’s Digital Signal Processing business.

John is a non-executive director of Intersec, the high velocity big data analytics company based in Paris.  He has served numerous firms in chair, board-member and advisory roles, including Intrinisty (Austin, TX), Innovative Silicon (Lausanne), ETA Devices (Cambridge, MA), CPS & Ubinetics (Cambridge, UK), SonIM (San Mateo), Netronome (Pittsburgh), Plessey, Samsung and Inphi (Santa Clara).

William Tunstall-Pedoe

Member of the Advisory Panel

William Tunstall-Pedoe was the founder of Cambridge start-up Evi (formerly True Knowledge), a company which has deep technology around understanding natural language and automatically answering questions on any topic. Following its acquisition, the technology became an integral part of Amazon’s Alexa and William held a senior role in the team that defined, built and launched Amazon Echo working with hundreds of scientists and engineers. Evi is now the Cambridge subsidiary of Amazon, employing hundreds of scientists and engineers locally from multiple projects including Alexa and Prime Air.

William is now an active angel investor and fellow of the Creative Destruction Lab, a Toronto based incubator for AI start-ups where he helps many tens of early stage machine learning businesses.

William has a first class honours degree, studying Computer Science at Churchill College, Cambridge. Less serious projects include a commercial chess-playing program, the first and only software which can solve and explain cryptic crossword clues and the AI anagram-generating software which was used by Dan Brown to create the anagrams that were integral to the plot of the Da Vinci Code book and movie.

Sir Gregory Winter

Member of the Advisory Panel

Sir Gregory Winter is Master of Trinity College, Cambridge and a Fellow of the Royal Society.  He is best known for his research and inventions relating to therapeutic antibodies made at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

Sir Greg has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009.

  • David Braben

    Member of the Advisory Panel

  • Charles Cotton

    Chairman of the Advisory Panel

  • Sir Richard Friend

    Member of the Advisory Panel

  • John Lee

    Member of the Advisory Panel

  • Ruth March

    Member of the Advisory Panel

  • Jonathan Milner

    Member of the Advisory Panel

  • Sir Keith Peters

    Member of the Advisory Panel

  • Andy Richards

    Member of the Advisory Panel

  • John Scarisbrick

    Member of the Advisory Panel

  • William Tunstall-Pedoe

    Member of the Advisory Panel

  • Sir Gregory Winter

    Member of the Advisory Panel